Loading…
← CockpitCompetitor Analysis › MEDPLUS.NS MedPlus Health Services Ltd.Open in the cockpit ↗

MedPlus Health Services Ltd.MEDPLUS.NSCompetitor analysis, valuation and peers

India · INR·Consumer Staples›Drugstore Chains
Momentum laggard 14
Mkt cap
$771M
US dollars, full cap
Free float
57%
of shares outstanding
$/day
$1.08M
20-day average traded
Fwd P/E
33.9×
forward earnings
ROIC−WACC
-2.2 pp
WACC 9.6%
Hurdle
+1 pp
Req g minus delivered
Next earnings
72 days
29 Jan 2027
Close · INR₹600.40
1D-1.4%
1W-2.3%
1M+0.2%
3M-9.7%
6M-35.8%
YTD-25.6%
1Y-23.5%
ATR %3.2%
Beta0.47
52w lowhigh41.3% off high

What MedPlus Health Services does

Employees: 27,686

MedPlus Health Services at a glance

Size MedPlus Health Services (MEDPLUS.NS) is an India Consumer Staples company (Drugstore Chains) with a market value of $771M, the 694th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹600.40 on 18 Nov 2026.

Performance Over six months the shares fell 35.8%, against +2.1% for the median peer and +3.8% for the India market (cap-weighted) — lowest of 16 in its peer set.

Growth Revenue grew 20.6% over the last twelve months (peer median +4.0%); the operating margin is 4.2% (peer median 4.4%).

Valuation It trades at 33.9× forward earnings against a peer median of 14.4× (most expensive of 9).

Price implies For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.2 points below its cost of capital (9.6% WACC).

Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 103MEDPLUS.NS 66
Six months, rebased to 100: MedPlus Health Services against the median of its 15 peers (local-currency closes).

MedPlus Health Services financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹75.9B₹68.9B₹61.4B₹56.2B₹45.6B
Revenue growth—+12%+9%+23%—
Gross profit₹6.64B₹6.27B₹5.08B₹3.74B₹2.67B
EBITDA₹6.31B₹6.10B₹4.90B₹3.56B₹2.68B
Net income₹2.11B₹2.20B₹1.50B₹655M₹498M
Free cash flown/a₹4.04B₹4.95B₹729M-₹582M
Capital expendituren/a₹1.23B₹594M₹844M₹1.69B
Total debt₹15.5B₹14.2B₹11.2B₹10.1B₹9.00B

Quarterly statements and history in the cockpit →

MedPlus Health Services competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%30140892673010172664303460359000278800272796270005046038836008336052669989MEDPLUS.NS6-month return →1-month return →
Up and to the right = strong over both horizons. MedPlus Health Services is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%10×20×30×9267303460359000272796276038836052669989MEDPLUS.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. MedPlus Health Services is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%0%20%30140830101726643034603590002788002727962731486038836008336052669989MEDPLUS.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. MedPlus Health Services is the large dot.

MedPlus Health Services competitors and peer comparison

How MedPlus Health Services compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

MedPlus Health Services against its 15 peers (data as of 18 Nov 2026)
MeasureMEDPLUS.NSPeer medianRank in peer set
1-month return+0.2%-1.3%7th highest of 16
6-month return-35.8%+2.1%lowest of 16
Distance from 52-week high-41.3%-29.8%8th lowest of 16
Revenue growth (TTM)+20.6%+4.0%3rd highest of 16
Operating margin4.2%4.4%8th lowest of 16
Forward P/E33.9×14.4×most expensive of 9
Growth the price implies (Req g, 7 yrs)18.6%-7.3%2nd most demanding of 14
Growth delivered (Del g)+17.6%+8.0%2nd highest of 14
Hurdle (Req g minus delivered)+1.0 pp-19.5 pp3rd most demanding of 14
ROIC minus cost of capital-2.2 pp+2.7 pp4th lowest of 16
EV / EBITDA13.3×5.9×most expensive of 6
Net debt / EBITDA1.9×0.1×2nd most indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
MedPlus Health Services MEDPLUS.NSIndia$771M-36%+21%4%33.9×18.6%+17.6%
Anhui Huaren Health Pharmaceutical 301408.SZChina$745M-32%+15%8%n/a-7.5%+23.3%
Genky DrugStores 9267.TJapan$728M+3%+8%5%13.9×n/an/a
Shu Yu Civilian Pharmacy 301017.SZChina$701M-11%+9%2%n/a1.1%+17.4%
Cawachi 2664.TJapan$562M+31%-1%2%n/a-6.1%0.0%
Qol 3034.TJapan$561M+26%+5%6%10.5×-16.6%+12.4%
Beijing Konruns Pharmaceutical 603590.SSChina$558M-33%-1%17%19.0×12.4%+2.7%
Luyan Pharma 002788.SZChina$514M-32%+3%3%n/a-0.4%+6.5%
Yixintang Pharmaceutical 002727.SZChina$1.16B+4%-2%3%16.6×-16.0%+6.5%
Ain 9627.TJapan$1.25B+2%+42%4%13.8×-6.5%+16.9%
Create SD 3148.TJapan$1.32B+3%+9%5%n/a-11.5%+8.0%
Landfar Bio-medicine 000504.SZChina$351M-22%+497%-2%n/an/an/a
LBX Pharmacy Chain Joint Stock 603883.SSChina$1.71B+13%+3%5%16.1×-10.7%+9.7%
Shanghai No. 1 Pharmacy 600833.SSChina$299M-22%+1%-1%n/a19.5%+6.1%
JZJ Chain Drugstore Corporation 605266.SSChina$293M-35%-5%0%6.2×-9.9%+14.8%
Sundrug 9989.TJapan$3.07B+10%+4%6%14.9×-7.3%+5.8%

Questions

Which companies are MedPlus Health Services's closest peers?
The cockpit's peer set: Anhui Huaren Health Pharmaceutical (301408.SZ), Genky DrugStores (9267.T), Shu Yu Civilian Pharmacy (301017.SZ), Cawachi (2664.T), Qol (3034.T), Beijing Konruns Pharmaceutical (603590.SS), Luyan Pharma (002788.SZ), Yixintang Pharmaceutical (002727.SZ).
Is MedPlus Health Services expensive compared with its peers?
On forward p/e it trades at 33.9× against a peer median of 14.4×, most expensive of 9 in its peer set. For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has MedPlus Health Services stock performed?
Over six months to 18 Nov 2026 the shares returned -35.8% against +2.1% for the median peer; over one year -23.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.